HC Wainwright Reiterates Buy Rating for Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics (NASDAQ:RPTXGet Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday, TipRanks reports. They currently have a $54.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 388.69% from the stock’s current price.

RPTX has been the subject of several other reports. Piper Sandler reduced their price target on Repare Therapeutics from $40.00 to $25.00 in a research report on Tuesday. The Goldman Sachs Group began coverage on Repare Therapeutics in a research report on Thursday, March 17th. They issued a “buy” rating and a $43.00 price target for the company. Stifel Nicolaus cut Repare Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Zacks Investment Research cut Repare Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repare Therapeutics has a consensus rating of “Buy” and an average target price of $44.50.

NASDAQ:RPTX traded up $0.68 during trading hours on Tuesday, reaching $11.05. The stock had a trading volume of 13,750 shares, compared to its average volume of 123,621. The stock has a 50 day simple moving average of $14.20 and a 200 day simple moving average of $19.14. Repare Therapeutics has a 12-month low of $9.86 and a 12-month high of $35.75. The stock has a market cap of $462.77 million, a P/E ratio of -3.92 and a beta of 0.60.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last released its earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative return on equity of 41.95% and a negative net margin of 1,406.68%. The business had revenue of $6.88 million during the quarter, compared to the consensus estimate of $3.54 million. As a group, equities research analysts expect that Repare Therapeutics will post -3.58 earnings per share for the current year.

In related news, major shareholder Bvf Partners L. P/Il bought 997,961 shares of the stock in a transaction dated Wednesday, January 19th. The stock was bought at an average price of $14.10 per share, with a total value of $14,071,250.10. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 30.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RPTX. Legal & General Group Plc grew its holdings in shares of Repare Therapeutics by 55.5% during the 4th quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock worth $83,000 after acquiring an additional 1,400 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Repare Therapeutics by 17.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,578 shares of the company’s stock worth $231,000 after buying an additional 1,599 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Repare Therapeutics by 28.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after acquiring an additional 1,873 shares in the last quarter. National Bank of Canada FI bought a new position in Repare Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Northern Trust Corp lifted its position in Repare Therapeutics by 32.6% in the 4th quarter. Northern Trust Corp now owns 20,991 shares of the company’s stock valued at $442,000 after acquiring an additional 5,161 shares in the last quarter. 69.41% of the stock is owned by institutional investors.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Articles

Analyst Recommendations for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.